Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Kayser S, Martínez-Cuadrón D, Rodriguez-Veiga R, Hänel M, Tormo M, Schäfer-Eckart K, Botella C, Stölzel F, Del Castillo TB, Keller U, Rodriguez-Medina C, Held G, Amigo ML, Schliemann C, Colorado M, Kaufmann M, Garcia MB, Krause S, Görner M, Jost E, Steffen B, Zukunft S, Platzbecker U, Ho AD, Baldus CD, Serve H, Müller-Tidow C, Thiede C, Bornhäuser M, Montesinos P, Röllig C, Schlenk RF (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 108

Pages Range: 2059-2066

Journal Issue: 8

DOI: 10.3324/haematol.2022.282127

Abstract

We retrospectively studied 97 acute myeloid leukemia patients with trisomy 19 (median age at diagnosis 57 years; range, 17- 83 years) treated between 2001 and 2019 within two multicenter study groups. Trisomy 19 occurred alone in ten (10.5%) patients, with additional abnormalities being present in non-complex karyotypes in eight (8%) patients and in complex karyotypes in 79 (82%) patients. Altogether, karyotypes characterized by trisomies only were present in 27 (28%) patients. Data on response and outcome of intensively treated patients were available for 92 cases. The median follow-up was 6.4 years (95% confidence interval [95% CI]: 2.9-9.0 years). The complete remission (CR) rate after induction therapy was 52% (48 patients); the early death rate was 10% (n=9). Notably, patients with trisomy 19 as the sole abnormality had a CR rate of 89%. Allogeneic hematopoietic stem cell transplantation (allo-HCT) was performed in 34 (35%) patients (CR, n=19; active disease, n=15). Five-year relapse-free and overall survival rates were 26% (95% CI: 16-43%) and 20% (95% CI: 13-31%), respectively. Overall survival rates were significantly higher in patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only (P=0.05). An Andersen-Gill model including allo-HCT as a time-dependent covariable on overall survival revealed that trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only was a favorable factor (hazard ratio [HR]=0.47; P=0.021); higher age at diagnosis had an adverse impact (10 years difference; HR=1.29; P=0.002), whereas allo-HCT did not have a beneficial impact (odds ratio=1.45; P=0.21). In our cohort, patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only had a high CR rate and better clinical outcome.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Mannheim Germany (DE) Hospital Universitario y Politécnico de La Fe Spain (ES) Hospital Clínico Universitario de Valencia Spain (ES) Hospital General Universitario de Alicante Doctor Balmis Spain (ES) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Central University Hospital of Asturias Spain (ES) Charité - Universitätsmedizin Berlin Germany (DE) Hospital Universitario de Gran Canaria Doctor Negrín Spain (ES) Westpfalz-Klinikum Germany (DE) Hospital General Universitario Morales Meseguer Spain (ES) Universitätsklinikum Münster Germany (DE) Marqués de Valdecilla University Hospital / Hospital Universitario de Marqués de Valdecilla (HUMV) Spain (ES) Robert-Bosch-Krankenhaus Germany (DE) Hospital Regional de Málaga Spain (ES) Klinikum Bielefeld Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Leipzig Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Klinikum Chemnitz Germany (DE)

How to cite

APA:

Kayser, S., Martínez-Cuadrón, D., Rodriguez-Veiga, R., Hänel, M., Tormo, M., Schäfer-Eckart, K.,... Schlenk, R.F. (2023). Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia. Haematologica, 108(8), 2059-2066. https://doi.org/10.3324/haematol.2022.282127

MLA:

Kayser, Sabine, et al. "Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia." Haematologica 108.8 (2023): 2059-2066.

BibTeX: Download